Modern antidiabetic drugs do more than lower sugar, they protect the heart and vessels. This review explains how. #PharmRev 🧪
https://ow.ly/nZLt50XMvsO
https://ow.ly/nZLt50XMvsO
January 2, 2026 at 2:00 PM
Modern antidiabetic drugs do more than lower sugar, they protect the heart and vessels. This review explains how. #PharmRev 🧪
https://ow.ly/nZLt50XMvsO
https://ow.ly/nZLt50XMvsO
Neuropeptides fine-tune the brain’s noradrenergic centre. This review maps how they regulate the locus coeruleus to shape behaviour. #PharmRev Danai Riga 🧪
https://ow.ly/SrCq50XMrCq
https://ow.ly/SrCq50XMrCq
December 29, 2025 at 2:01 PM
Neuropeptides fine-tune the brain’s noradrenergic centre. This review maps how they regulate the locus coeruleus to shape behaviour. #PharmRev Danai Riga 🧪
https://ow.ly/SrCq50XMrCq
https://ow.ly/SrCq50XMrCq
Dopamine doesn’t just drive reward; it guides our social lives. This review explores how dopamine regulates social behaviour across species. #PharmRev #Dopamine Nancy Padilla-Coreano Martínez-Rivera 🧪
https://ow.ly/hx0x50XARUX
https://ow.ly/hx0x50XARUX
December 3, 2025 at 2:01 PM
Dopamine doesn’t just drive reward; it guides our social lives. This review explores how dopamine regulates social behaviour across species. #PharmRev #Dopamine Nancy Padilla-Coreano Martínez-Rivera 🧪
https://ow.ly/hx0x50XARUX
https://ow.ly/hx0x50XARUX
Adenosine-driven immunosuppression remains a barrier in cancer therapy. Targeting adenosine A2A/A2B receptors offers a path to reprogram the tumor microenvironment and boost immunotherapy efficacy. Read more of this exciting new #PharmRev publication here: https://ow.ly/95rZ50Yfjxj 🧪
February 16, 2026 at 6:01 PM
Adenosine-driven immunosuppression remains a barrier in cancer therapy. Targeting adenosine A2A/A2B receptors offers a path to reprogram the tumor microenvironment and boost immunotherapy efficacy. Read more of this exciting new #PharmRev publication here: https://ow.ly/95rZ50Yfjxj 🧪
EPAC proteins reshape blood vessels. This review dissects cAMP-driven vascular remodeling and its therapeutic implications. #PharmRev #science 🧪
https://pharmrev.aspetjournals.org/article/S0031-6997(25)07486-1/abstract
https://pharmrev.aspetjournals.org/article/S0031-6997(25)07486-1/abstract
December 24, 2025 at 2:01 PM
EPAC proteins reshape blood vessels. This review dissects cAMP-driven vascular remodeling and its therapeutic implications. #PharmRev #science 🧪
https://pharmrev.aspetjournals.org/article/S0031-6997(25)07486-1/abstract
https://pharmrev.aspetjournals.org/article/S0031-6997(25)07486-1/abstract
Posttraumatic epilepsy remains untreatable. This review highlights new models and strategies for PTE prevention and therapy. #PharmRev #Epilepsy 🧪
https://ow.ly/EHRR50XMrre
https://ow.ly/EHRR50XMrre
December 26, 2025 at 2:01 PM
Posttraumatic epilepsy remains untreatable. This review highlights new models and strategies for PTE prevention and therapy. #PharmRev #Epilepsy 🧪
https://ow.ly/EHRR50XMrre
https://ow.ly/EHRR50XMrre
Targeting serotonin to treat neurodegeneration: this review explores how the serotonergic system could unlock new therapies for Alzheimer’s, Parkinson’s, and ALS. #PharmRev #Neuroscience #science 🧪
https://ow.ly/xK4z50XHqhf
https://ow.ly/xK4z50XHqhf
December 11, 2025 at 2:24 PM
Targeting serotonin to treat neurodegeneration: this review explores how the serotonergic system could unlock new therapies for Alzheimer’s, Parkinson’s, and ALS. #PharmRev #Neuroscience #science 🧪
https://ow.ly/xK4z50XHqhf
https://ow.ly/xK4z50XHqhf
The complement system is booming, 8 new drugs in 5 years! This review covers the biology, pathology, and therapeutic targeting of complement pathways. #PharmRev @neurocomplementlab.bsky.social 🧪
https://ow.ly/Tolg50XL5V5
https://ow.ly/Tolg50XL5V5
December 19, 2025 at 2:01 PM
The complement system is booming, 8 new drugs in 5 years! This review covers the biology, pathology, and therapeutic targeting of complement pathways. #PharmRev @neurocomplementlab.bsky.social 🧪
https://ow.ly/Tolg50XL5V5
https://ow.ly/Tolg50XL5V5
🧪Multiomics & machine learning are transforming how we predict, detect & treat atherosclerosis. Integrating genomics, proteomics, metabolomics, & more is paving the way to personalized cardiovascular care. Check out this #PharmRev paper to learn more: https://ow.ly/H41550YoMJt
#pharmsky
#pharmsky
March 4, 2026 at 3:01 PM
🧪Multiomics & machine learning are transforming how we predict, detect & treat atherosclerosis. Integrating genomics, proteomics, metabolomics, & more is paving the way to personalized cardiovascular care. Check out this #PharmRev paper to learn more: https://ow.ly/H41550YoMJt
#pharmsky
#pharmsky
Adenosine-driven immunosuppression remains a barrier in cancer therapy. Targeting adenosine A2A/A2B receptors offers a path to reprogram the tumor microenvironment and boost immunotherapy efficacy. Read more of this exciting new #PharmRev publication here: https://ow.ly/95rZ50Yfjxj 🧪
February 16, 2026 at 6:01 PM
Adenosine-driven immunosuppression remains a barrier in cancer therapy. Targeting adenosine A2A/A2B receptors offers a path to reprogram the tumor microenvironment and boost immunotherapy efficacy. Read more of this exciting new #PharmRev publication here: https://ow.ly/95rZ50Yfjxj 🧪
Research from @ucdavis.bsky.social highlights cutting-edge advances in the pharmacology of voltage-gated Na⁺, Ca²⁺, and K⁺ ion channels (VGIC) and showcases how protein structures and AI are shaping next-generation VGIC therapeutics. 🧪#PharmRev pharmrev.aspetjournals.org/article/S003...
February 5, 2026 at 3:12 PM
Research from @ucdavis.bsky.social highlights cutting-edge advances in the pharmacology of voltage-gated Na⁺, Ca²⁺, and K⁺ ion channels (VGIC) and showcases how protein structures and AI are shaping next-generation VGIC therapeutics. 🧪#PharmRev pharmrev.aspetjournals.org/article/S003...
EGFR drives many cancers, but resistance remains a challenge. This review decodes EGFR biology and emerging strategies to overcome therapy resistance. #PharmRev #cancertherapy #science 🧪
https://ow.ly/IiMg50XHqHK
https://ow.ly/IiMg50XHqHK
December 15, 2025 at 2:01 PM
EGFR drives many cancers, but resistance remains a challenge. This review decodes EGFR biology and emerging strategies to overcome therapy resistance. #PharmRev #cancertherapy #science 🧪
https://ow.ly/IiMg50XHqHK
https://ow.ly/IiMg50XHqHK
#Cardiovascular diseases remain the leading cause of death worldwide, with lipid-lowering drugs playing a key role in risk management. This review dives into the evolution of lipid-lowering treatments: https://ow.ly/sXkl50Y5u7W
#PharmRev 🧪
#PharmRev 🧪
January 29, 2026 at 4:12 PM
#Cardiovascular diseases remain the leading cause of death worldwide, with lipid-lowering drugs playing a key role in risk management. This review dives into the evolution of lipid-lowering treatments: https://ow.ly/sXkl50Y5u7W
#PharmRev 🧪
#PharmRev 🧪
It is also one of the fastest translation of fundamental discovery (in 1998) to treatments on the market (eg. suvorexant approved 2014). For more info on the peptides and drugs see DOI: 10.1124/pharmrev.123.000953. I've wondered why this discovery hasn't won big prizes.
November 19, 2025 at 5:33 PM
It is also one of the fastest translation of fundamental discovery (in 1998) to treatments on the market (eg. suvorexant approved 2014). For more info on the peptides and drugs see DOI: 10.1124/pharmrev.123.000953. I've wondered why this discovery hasn't won big prizes.
This exciting #PharmRev article takes an in-depth look at recent developments in the discovery and clinical significance of pharmacological agents targeting mammalian TRP channels: https://ow.ly/Xnov50YetJQ 🧪
February 13, 2026 at 2:02 PM
This exciting #PharmRev article takes an in-depth look at recent developments in the discovery and clinical significance of pharmacological agents targeting mammalian TRP channels: https://ow.ly/Xnov50YetJQ 🧪
Check out this recent #PharmRev review to explore the use of metal-based agents conjugated to tumor-targeting molecules for the treatment of #breastcancer.
Read the research: https://pharmrev.aspetjournals.org/article/S0031-6997(25)07495-2/abstract
Read the research: https://pharmrev.aspetjournals.org/article/S0031-6997(25)07495-2/abstract
January 27, 2026 at 2:57 PM
Check out this recent #PharmRev review to explore the use of metal-based agents conjugated to tumor-targeting molecules for the treatment of #breastcancer.
Read the research: https://pharmrev.aspetjournals.org/article/S0031-6997(25)07495-2/abstract
Read the research: https://pharmrev.aspetjournals.org/article/S0031-6997(25)07495-2/abstract
Reprogramming cells to heal organs, this review explores breakthroughs in cell and tissue reprogramming for regenerative drug discovery. #PharmRev 🧪
https://ow.ly/9KGW50XMnLp
https://ow.ly/9KGW50XMnLp
December 22, 2025 at 2:02 PM
Reprogramming cells to heal organs, this review explores breakthroughs in cell and tissue reprogramming for regenerative drug discovery. #PharmRev 🧪
https://ow.ly/9KGW50XMnLp
https://ow.ly/9KGW50XMnLp
📢 Hypoxia fuels tumor survival. This review from Gregg Semenza explores small-molecule inhibitors of HIF-1/2 as emerging cancer therapeutics. #PharmRev 🧪
https://ow.ly/jENZ50XJOVj
https://ow.ly/jENZ50XJOVj
December 17, 2025 at 2:01 PM
📢 Hypoxia fuels tumor survival. This review from Gregg Semenza explores small-molecule inhibitors of HIF-1/2 as emerging cancer therapeutics. #PharmRev 🧪
https://ow.ly/jENZ50XJOVj
https://ow.ly/jENZ50XJOVj